Exceeding climate targets in sustainable science
Integra Biosciences has made signifi cant progress in reducing its environmental footprint, far surpassing its initial carbon-reduction targets. As a participant in the Science Based Targets initiative (SBTi) - which provides independent validation of corporate climate commitments - the company has already cut scope 1 (direct) and scope 2 (energy-related) emissions by 57%. This milestone, achieved well ahead of schedule, places Integra fi rmly on track to meet all of its ambitious sustainability objectives.
The company’s emissions reduction targets were offi cially approved by the SBTi in 2023, and progress is assessed annually by the myclimate foundation. The 2024 report highlights that Integra reached in just three years a level of reduction it had originally aimed to achieve by 2031. In addition, it is making strong headway on its scope 3 target, covering indirect supply chain emissions, which were down by 28% at the close of 2024.
Despite these achievements, Integra is not slowing down. Current hotspots for emissions - particularly raw materials and transport - are being addressed with a range of new initiatives. These measures will ensure continued progress toward greener operations, supporting the wider scientifi c community’s transition to more sustainable practices.
Leadership shift sharpens focus on production excellence and global growth
Reductions in Integra’s scope 1 and 2 emissions from 2021 to 2024.
More information online:
ilmt.co/PL/WD0b 65820pr@reply-direct.com
L-R: Dr Mathias Schindler, COO and Member of the Executive Board and Dr Matthias Hohenleutner, newly appointed Vice President of Production. Credit: Toptica Photonics SE
Partnership expands oncology diagnostics across Europe
A fresh agreement between Bio-Rad Laboratories and Korean oncology specialist Gencurix will bring a new wave of molecular diagnostics to clinical labs across Europe. The deal makes Bio-Rad the exclusive distributor of Gencurix’s CE-IVD Droplex™ digital PCR testing kits, which are powered by Bio-Rad’s Droplet Digital™ PCR (ddPCR™) platform.
The Droplex assays are designed for highly sensitive detection of mutations from liquid biopsy and FFPE samples, with applications across major cancers such as melanoma, colorectal cancer, and non-small cell lung cancer. Used alongside Bio-Rad’s QXDx™ ddPCR systems, the kits aim to give clinicians sharper tools for guiding treatment decisions.
The extended partnership builds on an already established relationship between the two companies but takes it further with
joint marketing and collaborative development initiatives. For Gencurix, the agreement validates the clinical potential of its technology, while Bio-Rad strengthens its oncology diagnostics portfolio in one of the world’s most important markets.
“This partnership gives European labs access to highly sensitive diagnostic tools and will help physicians make more informed treatment decisions,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories.
“Expanding with Bio-Rad marks a milestone for Gencurix and accelerates access to our oncology diagnostics across Europe,” added Sang Rae Cho, CEO of Gencurix.
More information online:
ilmt.co/PL/1nMV 65913pr@reply-direct.com
Leadership change sparks next phase in antibody discovery growth
FairJourney Biologics (FJBio) has appointed Dr Werner Lanthaler as Chief Executive Offi cer, marking a new chapter for the antibody discovery specialist as it expands its global reach and data-driven innovation capabilities. Founder António Parada, who has led the
company since its inception, will transition to the Supervisory Board, focusing on innovation strategy and long-term vision.
Dr Lanthaler joins FJBio after 15 years as CEO of Evotec SE, where he transformed the company into a world leader in precision drug discovery. A strong advocate for platform-based science and AI integration, he brings a record of scaling collaborative R&D models that connect academia, biotech and pharma to accelerate therapeutic development.
“Shared data- and AI-driven innovation platforms will be critical to accelerating drug discovery while reducing development timelines and costs,” said Dr Lanthaler. “FairJourney Biologics is uniquely positioned to lead globally in delivering effi ciency gains throughout the entire ‘Gene to Clone’ process.”
Partners Group’s Pascal Noth, Head of Healthcare & Lifesciences Europe, praised the appointment:“FairJourney Biologics has grown from a bold idea in Porto into a global innovator. Under Werner’s leadership, the company will continue to deliver transformative advances in antibody discovery.”
With more than a decade of rapid growth behind it, FJBio now aims to build on its expertise in antibody engineering and AI-enhanced discovery to deliver faster, smarter solutions for the biopharma industry.
Dr. Werner Lanthaler. Credit: WLan Holding
More information online:
ilmt.co/PL/A8k4 65975pr@reply-direct.com
Toptica Photonics SE has announced that Dr Matthias Hohenleutner will become Vice President of Production from 1 October 2025, a move designed to reinforce the company’s manufacturing strength and prepare the ground for future growth.
Dr Hohenleutner, who has been with Toptica since 2016, brings both technical expertise and proven leadership to his new role. After joining as a project manager in R&D, he quickly advanced to head a team specialising in ultrafast custom laser systems and reference solutions. His close collaboration with production and business units has given him deep insight into the company’s manufacturing processes, making him a natural fit to lead the next phase of operational development.
“Matthias has a strong track record of building high-performing teams and driving innovation across
commented Dr Mathias Schindler, COO and Member of the Executive Board. “With him taking the helm of production, we can ensure continued excellence while also focusing more strongly on strategic initiatives.”
As part of the transition, Dr Schindler will step back from direct production oversight and concentrate on long-term priorities such as digitalisation, automation, and global competitiveness. This division of responsibilities is expected to strengthen both Toptica’s immediate operational resilience and its long-term strategic positioning.
Dr Wilhelm Kaenders, Founder and CTO of Toptica, praised the smooth handover: “We thank Mathias for nearly a decade of commitment to production leadership. His vision has shaped our manufacturing culture, and we are excited to see him now devote his energy to driving our future competitiveness.”
With more than 25 years of expertise in high-end laser systems, Toptica Photonics continues to expand its international presence. The appointment of Dr Hohenleutner reflects the company’s dual commitment to operational excellence and forward-looking innovation.
More information online:
ilmt.co/PL/ZOW5 65898pr@reply-direct.com
our organisation,”
To be included in our next issue, send all your News stories to:
gwyneth@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
